《药物基因组学》杂志,201210期,PGx与5FU,结直肠癌的化疗方案现状和未来.pdfVIP

Editorial For reprint orders, please contact: reprints@ Pharmacokinetic adaptation of 5-fluorouracil: where are we and where are we going? “...using the traditional body surface area calculation method, 43% of patients were not given the right dose: 33% were underdosed (significantly reduced efficacy) and 10% were overdosed (running a strong risk of severe early-onset toxicity).” KEYWORDS: 5‑FU n colorectal cancer n dose adjustment n fluoropyrimidines n personalized medicine n pharmacokinetic n PK n TDM n toxicity Michèle Boisdron-Celle Taking into account human Dose calculation: from body surface Institut de Cancérologie de l’Ouest, site heterogeneity to improve treatment area obsolescence towards new Paul Papin, Centre Recherche tolerance efficacy efficient TDM–PK methods Cancérologie Nantes Angers - INSERM U892, France Personalized medicine is fast becoming the new Since the 1950s, body surface area (BSA) has and paradigm in treatment management in oncology been used to calculate the dosage of many Département de Biopathologie du Cancer, Unité d’Oncopharmacologie et resulting in improved drug efficacy, avoidance drugs, but in the case of 5-FU, this method has Pharmacogénétique, Institut de of severe toxic reactions and